Matthias Barz

Dr. Matthias Barz

Institute of Organic Chemistry, Johannes Gutenberg-Universität Mainz, Mainz, Germany
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2015 in Nano Today
Verified
Journal Article
Closed access
MTMarina Talelli
Marina Talelli
Matthias BarzMatthias Barz
Matthias Barz
CRCristianne J.F. Rijcken
Cristianne J.F. Rijcken
Fabian KiesslingFabian Kiessling
Fabian Kiessling
WHWim E. Hennink
Wim E. Hennink
Twan LammersTwan Lammers
Twan Lammers

28 March 2011 in Polymer Chemistry
Verified
Journal Article
Closed access
PDF file
Matthias BarzMatthias Barz
Matthias Barz
RLRobert Luxenhofer
Robert Luxenhofer
RZRudolf Zentel
Rudolf Zentel
MVMaria Vicent
Maria Vicent
Synthetic methods in polymer chemistry have evolved tremendously during the last decade. Nowadays more and more attention is devoted to the application of those tools in the development of the next generation of nanomedicines. Nevertheless, poly(ethylene glycol) (PEG) remains the most frequently used polymer for biomedical applications. In this review, we try to summarize recent efforts and developments in controlled polymerisation techniques that may allow alternatives to PEG based systems and can be used to improve the properties of future polymer therapeutics.

25 September 2020 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
SNSara S. Nogueira
Sara S. Nogueira
ASAnne Schlegel
Anne Schlegel
KMKonrad Maxeiner
Konrad Maxeiner
BWBenjamin Weber
Benjamin Weber
Matthias BarzMatthias Barz
Matthias Barz
Heinrich HaasHeinrich Haas
Heinrich Haas

1 March 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
AAAlaaldin M Alkilany
Alaaldin M Alkilany
LZLin Zhu
Lin Zhu
HWHorst Weller
Horst Weller
AMAlf Mews
Alf Mews
WPWolfgang Parak
Wolfgang Parak
Neus  FeliuNeus Feliu
Neus Feliu

1 June 2018 in Progress in Polymer Science
Verified
Journal Article
Closed access
ABAlexander Birke
Alexander Birke
Jun LingJun Ling
Jun Ling
Matthias BarzMatthias Barz
Matthias Barz

6 April 2020 in Small
Verified
Journal Article
Open access
PDF file
IAIrina Alberg
Irina Alberg
SKStefan Kramer
Stefan Kramer
MSMeike Schinnerer
Meike Schinnerer
QHQizhi Hu
Qizhi Hu
CSChristine Seidl
Christine Seidl
RZRudolf Zentel
Rudolf Zentel
The current understanding of nanoparticle–protein interactions indicates that they rapidly adsorb proteins upon introduction into a living organism. The formed protein corona determines thereafter identity and fate of nanoparticles in the body. The present study evaluates the protein affinity of three core‐crosslinked polymeric nanoparticles with long circulation times, differing in the hydrophilic polymer material forming the particle surface, namely poly(N‐2‐hydroxypropylmethacrylamide) (pHPMA), polysarcosine (pSar), and poly(ethylene glycol) (PEG). This includes the nanotherapeutic CPC634, which is currently in clinical phase II evaluation. To investigate possible protein corona formation, the nanoparticles are incubated in human blood plasma and separated by asymmetrical flow field‐flow fractionation (AF4). Notably, light scattering shows no detectable differences in particle size or polydispersity upon incubation with plasma for all nanoparticles, while in gel electrophoresis, minor amounts of proteins can be detected in the particle fraction. Label‐free quantitative proteomics is additionally applied to analyze and quantify the composition of the proteins. It proves that some proteins are enriched, but their concentration is significantly less than one protein per particle. Thus, most of the nanoparticles are not associated with any proteins. Therefore, this work underlines that polymeric nanoparticles can be synthesized, for which a protein corona formation does not take place.